Processa Pharmaceuticals Inc (PCSA)

$2.80 +0.03 (1.08%)
Market Cap 7.37M
Revenue (ttm) 0.00
Net Income (ttm) -13.56M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 264,400
Avg Vol 51,308
Day's Range N/A - N/A
Shares Out 2.66M
Stochastic %K 61%
Beta 0.89
Analysts Sell
Price Target $25.00

Company Profile

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, whi...

Industry: Biotechnology
Sector: Healthcare
Phone: 772 453 2899
Fax: 443 288 4420
Address:
601 21st Street, Suite 300, Vero Beach, United States
Jwa68
Jwa68 Apr. 6 at 5:23 PM
$PCSA wonder if the plan is to try and reprice all the warrants from the last financing to raise desperately needed capital. Need some liquidity for them to short into if that is the plan imo.
0 · Reply
nopennys
nopennys Apr. 6 at 4:42 PM
$PCSA interested reignited here.
0 · Reply
Baraa_MD
Baraa_MD Apr. 6 at 3:52 PM
$PCSA so can we see a big movement soon?! 🤞🏼📈
1 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 6 at 1:42 PM
$PCSA lots of vol this AM
1 · Reply
Wallymarket
Wallymarket Apr. 6 at 1:36 PM
$MSAI the time will come same as $PFSA $PCSA $LNKS $MAXN
0 · Reply
Jwa68
Jwa68 Apr. 4 at 7:55 PM
$PCSA Dr. David Young back in Jan 22. "We have invested our time and our own money in Processa and its mission. We don’t believe value creation comes from bloated payrolls for executives in the C-suite; it comes from generating compelling clinical data. This is where we are allocating our resources. After uplisting on the Nasdaq, we demonstrated our personal commitments by limiting the combined cash compensation for our six C-suite members to less than $600K annually. This aligns our interests with our shareholders." It all sounded good but was it ever really genuine? Maybe they just changed their plans to no longer allign with shareholders? Take a look at today's payroll..if accurate, does it look a little bloated to anyone else? the CFO isn't even included, he is another almost $500K. Nice legacy Dr. Young. I always try to live ny life by the quote..."a man's word isn't any good, he's no good himself." My thoughts...you are welcome to your own but history tells.
0 · Reply
Jwa68
Jwa68 Apr. 4 at 12:15 AM
$PCSA Keep up the good work David. All a man has is his word at the end of the day. What happened to the 3 phase three trials you promised shareholders? Four years later and the only people who benefitted are you and your team. Nice legacy my old friend.
0 · Reply
Jwa68
Jwa68 Apr. 3 at 6:29 PM
$PCSA
0 · Reply
Tetoooo
Tetoooo Apr. 3 at 3:55 PM
$PCSA it will fly in a way you won’t expect.
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Apr. 3 at 1:37 PM
$PCSA - A very possible outcome here is what happened to $LPTX in November 2025. We already are buying CHZ coin as a treasury. Dreyfus is here for a reason. $LPTX spiked 500% on the news btw. https://www.prnewswire.com/news-releases/leap-therapeutics-rebrands-as-cypherpunk-expands-leadership-team-to-drive-new-zcash-treasury-strategy-302612466.html
1 · Reply
Latest News on PCSA
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 9:15 AM EST - 3 months ago

Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Jan 5, 2026, 9:15 AM EST - 3 months ago

Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Dec 17, 2025, 1:10 PM EST - 3 months ago

Why Is Small-Cap Processa Pharmaceuticals Stock Rallying After Breast Cancer Trial Data?

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Dec 17, 2025, 8:00 AM EST - 3 months ago

Processa Pharmaceuticals Provides Clinical Update on Phase 2 Study in Metastatic Breast Cancer

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Nov 5, 2025, 9:15 AM EST - 5 months ago

Processa Pharmaceuticals Announces Poster Presentation of Adaptive Phase 2/3 PCS499 Study in FSGS at ASN Kidney Week 2025

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Aug 7, 2025, 8:30 AM EDT - 8 months ago

Processa Pharmaceuticals Secures Strategic Investment and Evaluates Corporate Crypto Treasury Strategies

Processa Pharmaceuticals Provides Portfolio and Business Update

Jul 1, 2025, 9:00 AM EDT - 10 months ago

Processa Pharmaceuticals Provides Portfolio and Business Update

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Jun 17, 2025, 12:26 PM EDT - 10 months ago

Processa Pharmaceuticals Announces Pricing of $7 Million Public Offering

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Jun 17, 2025, 9:00 AM EDT - 10 months ago

Processa Pharmaceuticals Signs Binding Term Sheet Granting Intact Therapeutics Exclusive Option to License Phase 2 Gastroparesis Drug Candidate

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Jun 13, 2025, 8:00 AM EDT - 10 months ago

Processa Pharmaceuticals to Engage Potential Partners and Investors at BIO International Convention 2025

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

May 30, 2025, 9:00 AM EDT - 11 months ago

Processa Pharmaceuticals Announces Presentation and Publication of Three Abstracts at 2025 ASCO Annual Meeting

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals' Dr. David Young to Present at World Orphan Drug Congress USA 2025

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Mar 18, 2025, 8:30 AM EDT - 1 year ago

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Feb 7, 2025, 8:00 AM EST - 1 year ago

Processa Pharmaceuticals to Present at the 2025 BIO CEO & Investor Conference

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 30, 2025, 5:17 PM EST - 1 year ago

Processa Pharmaceuticals Announces Closing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Jan 27, 2025, 8:30 PM EST - 1 year ago

Processa Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Oct 2, 2024, 4:05 PM EDT - 1 year ago

Processa Pharmaceuticals Announces First Patient Dosed in Phase 2 Clinical Trial of NGC-Cap in Metastatic Breast Cancer

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Processa Pharmaceuticals to Participate in Investor and Industry Conferences During September

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Jun 11, 2024, 8:20 AM EDT - 1 year ago

Processa Pharmaceuticals Announces Positive Efficacy Results from Preliminary Evaluation of Phase 1b Dose-escalating Trial with NGC-Cap in Gastrointestinal Cancer

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

May 6, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals to Participate in the EF Hutton Annual Global Conference

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Apr 30, 2024, 8:00 AM EDT - 2 years ago

Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Mar 25, 2024, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Feb 21, 2024, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Feb 14, 2024, 1:00 PM EST - 2 years ago

Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Feb 6, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Feb 1, 2024, 4:22 PM EST - 2 years ago

Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

Jan 26, 2024, 9:04 AM EST - 2 years ago

Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Jan 25, 2024, 11:29 AM EST - 2 years ago

What made Processa Pharmaceuticals stock nearly triple on Thursday?

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Jan 25, 2024, 8:30 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Jan 19, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Jan 18, 2024, 7:45 AM EST - 2 years ago

Processa Pharmaceuticals to Effect a 1-for-20 Reverse Stock Split

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Jan 2, 2024, 5:06 PM EST - 2 years ago

Processa Pharmaceuticals to Present at the Biotech Showcase 2024

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Dec 19, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Provides Interim Analysis from Ongoing Phase 1b Trial of Next Generation Capecitabine Showing Improved Safety Over Capecitabine

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Dec 13, 2023, 9:00 AM EST - 2 years ago

Processa Pharmaceuticals Announces Successful Phase 2 Meeting with FDA for Next Generation Capecitabine

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Nov 30, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Nov 29, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals Issues Letter to Shareholders Highlighting Corporate Strategy, Drug Pipeline, and Outlook

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Nov 13, 2023, 1:40 PM EST - 2 years ago

Processa Pharmaceuticals, Inc. Mourns the Sudden Passing of Board Member Virgil Thompson

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Nov 9, 2023, 8:15 AM EST - 2 years ago

Processa Pharmaceuticals to Present at the 20th Orphan Drugs and Rare Diseases Global Congress 2023 Americas

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Nov 1, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Oct 13, 2023, 1:08 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the ThinkEquity Conference

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Sep 6, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Aug 17, 2023, 8:05 AM EDT - 2 years ago

Processa Pharmaceuticals Provides Data Update Supporting a Potential Personalized Treatment Approach for Improved Cancer Care

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Aug 10, 2023, 4:15 PM EDT - 2 years ago

Processa Pharmaceuticals to Present at the Sidoti & Co. Micro Cap Virtual Conference

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Aug 8, 2023, 8:15 AM EDT - 2 years ago

Processa Pharmaceuticals Appoints Life Sciences Industry Veteran George Ng as Chief Executive Officer

Next Generation Chemotherapy: Improved Treatment for More Patients

Jun 14, 2023, 4:15 PM EDT - 3 years ago

Next Generation Chemotherapy: Improved Treatment for More Patients

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

May 22, 2023, 8:05 AM EDT - 3 years ago

Processa Pharmaceuticals to Participate in a Panel on Interaction with the FDA at the World Orphan Drug Congress

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

May 18, 2023, 8:00 AM EDT - 3 years ago

Processa Pharmaceuticals to Conduct Next Generation Chemotherapy-Capecitabine Phase 2 Trial Based on FDA Guidance and Project Optimus Oncology Initiative

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Apr 28, 2023, 8:15 AM EDT - 3 years ago

Processa Pharmaceuticals to Present PCS12852 Gastroparesis Results at the Digestive Disease Week 2023 Annual Meeting

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Mar 30, 2023, 4:01 PM EDT - 3 years ago

Processa Pharmaceuticals Provides Corporate Update and Announces Year End 2022 Financial Results

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Mar 23, 2023, 8:30 AM EDT - 3 years ago

Processa Pharmaceuticals to Host Conference Call to Discuss 2022 Year End Results and Provide Drug Development Update on March 30, 2023 at 4:30 p.m. EST

Jwa68
Jwa68 Apr. 6 at 5:23 PM
$PCSA wonder if the plan is to try and reprice all the warrants from the last financing to raise desperately needed capital. Need some liquidity for them to short into if that is the plan imo.
0 · Reply
nopennys
nopennys Apr. 6 at 4:42 PM
$PCSA interested reignited here.
0 · Reply
Baraa_MD
Baraa_MD Apr. 6 at 3:52 PM
$PCSA so can we see a big movement soon?! 🤞🏼📈
1 · Reply
skyrockets_Inc
skyrockets_Inc Apr. 6 at 1:42 PM
$PCSA lots of vol this AM
1 · Reply
Wallymarket
Wallymarket Apr. 6 at 1:36 PM
$MSAI the time will come same as $PFSA $PCSA $LNKS $MAXN
0 · Reply
Jwa68
Jwa68 Apr. 4 at 7:55 PM
$PCSA Dr. David Young back in Jan 22. "We have invested our time and our own money in Processa and its mission. We don’t believe value creation comes from bloated payrolls for executives in the C-suite; it comes from generating compelling clinical data. This is where we are allocating our resources. After uplisting on the Nasdaq, we demonstrated our personal commitments by limiting the combined cash compensation for our six C-suite members to less than $600K annually. This aligns our interests with our shareholders." It all sounded good but was it ever really genuine? Maybe they just changed their plans to no longer allign with shareholders? Take a look at today's payroll..if accurate, does it look a little bloated to anyone else? the CFO isn't even included, he is another almost $500K. Nice legacy Dr. Young. I always try to live ny life by the quote..."a man's word isn't any good, he's no good himself." My thoughts...you are welcome to your own but history tells.
0 · Reply
Jwa68
Jwa68 Apr. 4 at 12:15 AM
$PCSA Keep up the good work David. All a man has is his word at the end of the day. What happened to the 3 phase three trials you promised shareholders? Four years later and the only people who benefitted are you and your team. Nice legacy my old friend.
0 · Reply
Jwa68
Jwa68 Apr. 3 at 6:29 PM
$PCSA
0 · Reply
Tetoooo
Tetoooo Apr. 3 at 3:55 PM
$PCSA it will fly in a way you won’t expect.
1 · Reply
SDBiotechInvestor
SDBiotechInvestor Apr. 3 at 1:37 PM
$PCSA - A very possible outcome here is what happened to $LPTX in November 2025. We already are buying CHZ coin as a treasury. Dreyfus is here for a reason. $LPTX spiked 500% on the news btw. https://www.prnewswire.com/news-releases/leap-therapeutics-rebrands-as-cypherpunk-expands-leadership-team-to-drive-new-zcash-treasury-strategy-302612466.html
1 · Reply
Jwa68
Jwa68 Apr. 2 at 11:52 PM
$PCSA I completely agree, I see no data anytime soon personally. Data was promised mid last year, then promised year end, and now they again moved it to Q2. They also appear to have possibly stopped enrollment beyond the first 20 patients, I guess due to financial constraints? Anyone else notice the sites stopped recruiting a couple weeks back or so, assuming I'm right. Beyond that, the lawsuit with the drugs owner who terminated the license agreement appears to be coming to a possible head in upcoming months. I have always speculated they may lose the suit and the drug, notwithstanding some sort of settlement. Hopefully there are enough naive retail investors out there willing to take a very risky flyer so they can raise a little money to hang on until they can complete a merger with someone else, likely one of Dreyfus's crypto companies. I assume the DAT and crypto market meltdown hurt their effort to get a deal done as the space has soured so much in the last few months.
0 · Reply
Jwa68
Jwa68 Apr. 2 at 10:04 PM
$PCSA For my gambling friends...I'm reminded of the old saying. "If you can't spot the sucker at the table within the first half-hour, then you are the sucker."
0 · Reply
Goldengun23
Goldengun23 Apr. 2 at 9:27 PM
$PCSA another form 4!
0 · Reply
StocktwitsNews
StocktwitsNews Apr. 2 at 9:20 PM
PCSA Stock Rallies 10% After Hours— Here’s Why $PCSA $VXF https://stocktwits.com/news/equity/markets/pcsa-rallies-after-hours-heres-why/cZ7UdygRI8u
1 · Reply
Digitalization2026
Digitalization2026 Apr. 2 at 8:44 PM
$SRXH 👀 After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ
0 · Reply
topstockalerts
topstockalerts Apr. 2 at 8:33 PM
After Hours Top Gainers PT2 $YAAS $IMTE $PCSA $PLRZ $PMAX
0 · Reply
Shallu
Shallu Apr. 2 at 6:05 PM
$PCSA we need to break 5$ to get 20$🙏🏼
0 · Reply
Kinderla
Kinderla Apr. 2 at 5:50 PM
$PCSA Elaborate please on the DataVault angle. I’m beginning some searches but I don’t see anything. I know Alexandre Dreyfus recent ones a 13% position, and he is a Tech/Crypto heavyweight, but I don’t see anything direct link.
2 · Reply
Kinderla
Kinderla Apr. 2 at 4:41 PM
$PCSA Also, I am not affiliated with http://BioStockInfo.com in any way. I simply am grateful for the website and want to share it with as many serious investors as I can.
0 · Reply
Kinderla
Kinderla Apr. 2 at 4:40 PM
$PCSA I found this stock on http://BioStockInfo.com If you invest in BioTech you really should take a look. The editor Alex outs a lot of time and effort into it. It is totally free and is not the typical pump and dump stuff you see on this board. Alex puts out a Weekly Scanner that focuses on stocks with upcoming catalysts. The link is for last week and features PCSA at the #4 position: https://www.biostockinfo.com/biotech-catalyst-ai-scanner-march-wk4/ Take a look. If you are a serious investor, you will not be disappointed. Check out the last feature article on MLTX.
2 · Reply
Jwa68
Jwa68 Apr. 2 at 4:35 PM
$PCSA And the promo appears on just as telegraphed and predicted. Take your profits when you have them, financing likely imminent. Nice to see the little token insider purchases apparent "ploy" working just as designed. Predictable, like death and taxes. Keep up the good work guys.
1 · Reply
Kinderla
Kinderla Apr. 2 at 4:07 PM
$PCSA SDBio…since you are heavily invested, what do you know about the warrant overhang?How many and where are the strike prices? I’m getting conflicting info. Thanks in advance!
2 · Reply